| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.87▼ | 2.86▼ | 2.86▼ | 2.79▲ | 2.92▼ |
| MA10 | 2.86▼ | 2.87▼ | 2.91▼ | 2.69▲ | 2.66▲ |
| MA20 | 2.86▼ | 2.90▼ | 2.88▼ | 2.81▲ | 2.04▲ |
| MA50 | 2.87▼ | 2.83▼ | 2.74▲ | 2.62▲ | 2.05▲ |
| MA100 | 2.90▼ | 2.72▲ | 2.72▲ | 1.96▲ | 4.20▼ |
| MA200 | 2.88▼ | 2.75▲ | 2.83▲ | 1.98▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | -0.014▼ | -0.016▼ | -0.006▼ | 0.129▲ |
| RSI | 37.510▼ | 43.209▼ | 49.321▼ | 52.998▲ | 58.875▲ |
| STOCH | 62.963 | 9.360▼ | 16.307▼ | 69.456 | 75.639 |
| WILL %R | -100.000▼ | -100.000▼ | -89.362▼ | -31.825 | -23.214▲ |
| CCI | -116.349▼ | -81.229 | -62.005 | 130.824▲ | 68.505 |
|
Thursday, August 07, 2025 04:10 PM
Research and development and general administrative expenses (GAAP) decreased year over year. This decrease resulted in a 15.6% reduction in net loss for Q2 2025 compared to Q2 2024. Strong clinical ...
|
|
Thursday, August 07, 2025 01:26 PM
Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease Data from the Phase 2 study of VTX2735 in patients with ...
|
|
Thursday, July 10, 2025 10:50 AM
Ventyx Biosciences, Inc. (VTYX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 3.03 | 3.0494 | 2.83 | 2.83 | 702,548 |
| 14/08/25 | 2.83 | 3.01 | 2.79 | 3.00 | 510,757 |
| 13/08/25 | 2.70 | 2.935 | 2.665 | 2.85 | 1,099,614 |
| 12/08/25 | 2.69 | 2.725 | 2.54 | 2.63 | 982,133 |
| 11/08/25 | 2.82 | 2.86 | 2.635 | 2.64 | 750,267 |
| 08/08/25 | 2.41 | 2.88 | 2.405 | 2.81 | 1,889,454 |
| 07/08/25 | 2.56 | 2.598 | 2.36 | 2.36 | 686,400 |
| 06/08/25 | 2.56 | 2.57 | 2.415 | 2.53 | 696,300 |
| 05/08/25 | 2.74 | 2.76 | 2.58 | 2.58 | 467,504 |
| 04/08/25 | 2.65 | 2.745 | 2.60 | 2.72 | 287,931 |
|
|
||||
|
|
||||
|
|